HORMONAL PROFILE AND HELPFUL RESULTS REPRODUCTIVE TECHNOLOGIES IN FEMALE PATIENTSWITH DIFFERENT FORMS OF STERILITY

Authors

  • Mamadzhanova Khadicha Habibullaevna

    Central Asian Medical University, Fergana, Uzbekistan

    Author

  • Tashpulatova Makhliyo Pazildzhanovna

    Central Asian Medical University, Fergana, Uzbekistan

    Author

Keywords:
Infertility, auxiliary reproductive technologies, hormonal profile, antimuller hormone, SPKIA, fertility.
Abstract

Target:To evaluate the hormonal profile and identify the determinants that determine the effectiveness of the extracorporeal fertilization program (ЕКО) in patients with various etiological infertility.
Materials and Methods: Retrospectively analyzed data of 301 women who passed cycles of ЕКО/ИКСИ in 2021–2025. The concentrations of prolactin, thyrotropin hormone (ТТГ), follicle stimulating hormone (FSH), luteinizing hormone (ЛГ), estradiol, progesterone and antimullerova hormone (АМГ) are investigated. Statistical processing included descriptive statistics, Student's t-test and Pearson correlation analysis. Statistical significance was established at p < 0,05.

References

1. World Health Organization. Infertility definitions and terminology. Geneva: WHO; 2023.

2. Zegers-Hochschild F, Adamson GD, Dyer S, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. 2017;108(3):393-406.

3. Sunkara SK, Pundir J, Khalaf Y. Effect of androgen supplementation on the ovarian response to exogenous gonadotropins. Cochrane Database Syst Rev. 2011;(11):CD009224.

4. Iliodromiti S, Kelsey TW, Wu O, et al. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception. Hum Reprod. 2014;29(3):583-589.

5. Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2021;116(4):880-885.

6. Luke B, Brown MB, Wantman E, et al. The effect of maternal age and race on the live birth rate. Fertil Steril. 2014;101(3):e17.

7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.

8. Broekmans FJ, Visser JA, Laven JS, et al. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab. 2008;19(9):340-347.

9. Law DC, Kort JD. Age-related fertility decline. Obstet Gynecol Clin North Am. 2022;49(4):617-627.

10. Shoham Z, Jacobs HS, Insler V. Luteinizing hormone: its role, mechanism of action, and detrimental effects when hypersecreted during the follicular phase. Fertil Steril. 1993;59(6):1153-1161.

11. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1-13.

12. Strandell A, Lindhard A. Why does hydrosalpinx reduce fertility? The importance of hydrosalpinx fluid. Hum Reprod. 2002;17(5):1141-1145.

13. Hirahara F, Andoh N, Sawai K, et al. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril. 1998;70(2):246-252.

Downloads
Published
2026-06-06
Issue
Vol. 2 No. 6 (2026)
Section
Articles
License
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

HORMONAL PROFILE AND HELPFUL RESULTS REPRODUCTIVE TECHNOLOGIES IN FEMALE PATIENTSWITH DIFFERENT FORMS OF STERILITY. (2026). Eureka Journal of Health Sciences & Medical Innovation, 2(6), 155-167. https://eurekaoa.com/index.php/5/article/view/1239